Valeant Pharmaceuticals International, Inc. Completes Acquisition of Bausch + Lomb

By

LAVAL, Quebec— Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced it has completed the previously announced acquisition of Bausch + Lomb Holdings Incorporated.

Valeant is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. Its deal to acquired Bausch + Lomb was originally announced in May, as reported by VMail. The company said at that time that the cash deal will help it capitalize on increasing demand for contact lenses and other products because of aging populations, growing demand in emerging markets and increasing rates of diabetes.

Bausch + Lomb’s broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and VICTUS.

With the closing of the deal, investment firm Warburg Pincus, which leads an investment group that owns Bausch + Lomb, will receive $4.5 billion in cash. The remaining $4.2 billion will be used to repay Bausch + Lomb’s debt.